KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Assets (2016 - 2025)

Regeneron Pharmaceuticals has reported Non-Current Assets over the past 17 years, most recently at $22.5 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $22.5 billion for Q4 2025, up 18.0% from a year ago — trailing twelve months through Dec 2025 was $86.1 billion (up 23.45% YoY), and the annual figure for FY2025 was $22.5 billion, up 18.0%.
  • Non-Current Assets for Q4 2025 was $22.5 billion at Regeneron Pharmaceuticals, up from $22.2 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for REGN hit a ceiling of $22.5 billion in Q4 2025 and a floor of $7.7 billion in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $13.6 billion (2023), compared with a mean of $14.8 billion.
  • Biggest five-year swings in Non-Current Assets: soared 56.05% in 2022 and later increased 2.03% in 2023.
  • Regeneron Pharmaceuticals' Non-Current Assets stood at $11.4 billion in 2021, then grew by 16.73% to $13.3 billion in 2022, then increased by 2.03% to $13.6 billion in 2023, then skyrocketed by 40.42% to $19.1 billion in 2024, then rose by 18.0% to $22.5 billion in 2025.
  • The last three reported values for Non-Current Assets were $22.5 billion (Q4 2025), $22.2 billion (Q3 2025), and $21.4 billion (Q2 2025) per Business Quant data.